Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
ClinicalTrials.gov Studies
Summary
NIH ClinicalTrials.gov has registered NCT07537959, a randomized trial evaluating whether adding primary tumor resection to standard immune-based systemic therapy improves survival in hepatocellular carcinoma patients with extrahepatic metastases. The study will enroll approximately 252 participants and measure overall survival as the primary endpoint.
What changed
NIH ClinicalTrials.gov has registered a new clinical trial (NCT07537959) evaluating surgery plus systemic therapy versus systemic therapy alone for hepatocellular carcinoma patients with extrahepatic metastases. The randomized trial will assess primary tumor resection combined with protocol-allowed first-line immune-based systemic therapy, with overall survival as the primary outcome measure.
This trial registration applies to clinical investigators and trial sponsors conducting interventional studies. Parties conducting applicable clinical trials must ensure registration on ClinicalTrials.gov per FDAAA 801 requirements and maintain compliance with NIH formatting and update requirements.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
N/A NCT07537959 Kind: NA Apr 17, 2026
Abstract
This study will evaluate whether resection of the primary liver tumor, in addition to standard first-line systemic therapy, improves survival in patients with hepatocellular carcinoma that has spread outside the liver but still has a resectable primary intrahepatic tumor. Participants will be randomly assigned to receive either primary tumor resection followed by protocol-allowed first-line immune-based systemic therapy or systemic therapy alone. The primary outcome is overall survival. Secondary outcomes include progression-free survival, objective response rate, disease control rate, immune-related adverse events, postoperative complications, and quality of life.
Conditions: Hepatocellular Carcinoma (HCC), Metastasis
Interventions: Primary Tumor Resection, Protocol-Allowed First-Line Immune-Based Systemic Therapy
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.